Novel drug compound inhibiting skin cancer discovered: NCCS Study

Posted on:13 Aug 2016 18:13:36

Novel drug compound inhibiting skin cancer discovered: NCCS Study
13 August 2016 Current Affairs GK: Researchers from the Pune-based National Centre for Cell Science (NCCS) have successfully isolated cancer stem cells that cause skin cancer. 

They have successfully demonstrated that Andrographolide (a compound) isolated and purified from Andrographis paniculata (a herb) found in India is effective in inhibiting tumour growth both in skin cancer and lung metastasis in mice.

In order to establish that CD133 positive cancer stem cells cause cancer, the researchers had injected these cells subcutaneously into mice. 

The CD133 positive cancer stem cells that develops tumour faster than non-cancer stem cells. It also produces lung metastasis in a different set of mice that received the cells through intravenous injection. 

The research showed that all the animals injected with CD133 positive cancer stem cells developed skin cancer (melanoma). When the compound Andrographolide was injected in the mice, it inhibiting tumour growth both in skin cancer and lung metastasis.

Significance of Research  : The study indicates that the compound Andrographolide has therapeutic potential for the management of cancer stem-cell mediated melanoma growth and lung metastasis. The compound has ability to inhibit CD133 positive cancer stem cells growth which mediates tumour growth and lung metastasis. It also shows enhanced ability to flush out cancer drugs from inside the cells thereby increasing the probability of tumour relapse.

Gk Current Affairs April 2017

25 APRIL
NEWS
24 APRIL
NEWS
22 APRIL
NEWS
21 APRIL
NEWS

Gk Current Affairs March 2017

31 MARCH
NEWS
30 MARCH
NEWS
29 MARCH
NEWS
28 MARCH
NEWS

Gk Current Affairs February 2017

28 FEBRUARY
NEWS
27 FEBRUARY
NEWS
25 FEBRUARY
NEWS
24 FEBRUARY
NEWS




Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.

Get Daily Current Affairs to your Email

You can Unsubscribe us at any time.